乳腺导管内癌伴微浸润的病理和免疫组织化学特征分析  

Analysis of Pathological and Immunohistochemical Features of Breast Ductal Carcinoma in Situ with Microinvasion

作　　者：徐明[1] 叶辉[2] 叶曼娜 余燕民[3] 

机构地区：[1]上海市黄浦区中心医院病理科,上海200002 [2]上海市黄浦区中心医院外科,上海200002 [3]上海市黄浦区中心医院乳腺外科,上海200002

出　　处：《中国临床医学》2015年第2期224-227,共4页Chinese Journal of Clinical Medicine

基　　金：上海市黄浦区优秀学科带头人项目;黄浦区卫计委科研项目(编号:HKW201412)

摘　　要：目的:比较乳腺导管内癌伴微浸润(ductal carcinoma in situ with microinvasion,DCIS-MI)及导管内癌(ductal carcinoma in situ,DCIS)的病理和免疫组织化学特征。方法:收集176例DCIS-MI和184例DCIS患者的临床资料,对其病理和免疫组织化学特征进行分析。结果:两者肿块最大径≥2.5 cm、高级别组织分级、粉刺型组织亚型比例差异均有统计学意义(P<0.01);乳头paget病及腋窝淋巴结转移的患者比例差异无统计学意义(P>0.05);免疫组织化学标志物雌激素受体(estrogen receptor,ER)、孕激素受体(progesterone receptor,PR)、人表皮生长因子受体(human epidermal growth factor receptor 2,HER2)、Ki-67、小凹蛋白(caveolin-1)表达差异均有统计学意义(P<0.05)。结论:DCIS-MI在高级别组织分级、粉刺型组织亚型、肿块最大径≥2.5 cm、ER阴性、PR阴性、caveolin-1阴性、HER2阳性、Ki-67增殖指数≥14%的发生率高。Objective：To compare the clinicopathological and immunohistochemical features of ductal carcinoma in situ（DCIS） with those of DCIS with microinvasion（DCIS‐MI） .Methods：The clinical data of 176 cases of DCIS‐MI and 184 cases of DCIS were collected and the clinicopathological and immunohistochemical features were analyzed .Results：The differences between the proportion of tumor maximal diameter≥2 .5 cm ,high grade ,comedo subtype in DCIS‐MI and those in DCIS ,were statistically significant（P〈0 .01） .The differences in proportions of nipple with paget’s disease and axillary lymph node metastasis between the two groups were not statistically significant（P〉 0 .05） .The difference between the two groups in immunohistochemical markers estrogen receptor（ER）,progesterone receptor（PR）,human epidermal growth factor receptor 2（HER2）,Ki‐67 , caveolin‐1 expression was statistically significant（P〈0 .05） .Conclusion：DCIS‐MI shows high incidence in high grade ,comedo subtype ,tumor maximal diameter ≥ 2 .5 cm , ER negative , PR negative , caveolon‐1 positive , HER2‐positive , Ki‐67 proliferation index≥14% .

关 键 词：乳腺癌 导管内癌伴微浸润 导管内癌 免疫组织化学 

分 类 号：R737.9[医药卫生—肿瘤]